These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 18078515)
1. Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity. Redondo M; Téllez T; Roldan MJ; Serrano A; García-Aranda M; Gleave ME; Hortas ML; Morell M Breast Cancer Res; 2007; 9(6):R86. PubMed ID: 18078515 [TBL] [Abstract][Full Text] [Related]
2. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453 [TBL] [Abstract][Full Text] [Related]
3. Downregulation of clusterin mediates sensitivity to protein kinase inhibitors in breast cancer cells. Redondo M; García-Aranda M; Roldan MJ; Callejón G; Serrano A; Jiménez E; Téllez T Anticancer Drugs; 2015 Jan; 26(1):85-9. PubMed ID: 25144344 [TBL] [Abstract][Full Text] [Related]
4. Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2. Rubenstein M; Tsui P; Guinan P Med Oncol; 2010 Sep; 27(3):592-9. PubMed ID: 19533419 [TBL] [Abstract][Full Text] [Related]
5. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. So A; Sinnemann S; Huntsman D; Fazli L; Gleave M Mol Cancer Ther; 2005 Dec; 4(12):1837-49. PubMed ID: 16373699 [TBL] [Abstract][Full Text] [Related]
6. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. Lourda M; Trougakos IP; Gonos ES Int J Cancer; 2007 Feb; 120(3):611-22. PubMed ID: 17096323 [TBL] [Abstract][Full Text] [Related]
7. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636 [TBL] [Abstract][Full Text] [Related]
8. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells. Lee J; Gollahon L Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795 [TBL] [Abstract][Full Text] [Related]
9. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer. Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998 [TBL] [Abstract][Full Text] [Related]
10. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446 [TBL] [Abstract][Full Text] [Related]
11. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Gewirtz DA; Di X; Walker TD; Sawyer ST Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039 [TBL] [Abstract][Full Text] [Related]
12. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222 [TBL] [Abstract][Full Text] [Related]
13. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mallory JC; Crudden G; Oliva A; Saunders C; Stromberg A; Craven RJ Mol Pharmacol; 2005 Dec; 68(6):1747-56. PubMed ID: 16150928 [TBL] [Abstract][Full Text] [Related]
14. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082 [TBL] [Abstract][Full Text] [Related]
15. BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells. Prashanth Kumar BN; Rajput S; Bharti R; Parida S; Mandal M Biomed Pharmacother; 2015 Aug; 74():124-32. PubMed ID: 26349973 [TBL] [Abstract][Full Text] [Related]
16. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281 [TBL] [Abstract][Full Text] [Related]
17. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472 [TBL] [Abstract][Full Text] [Related]
18. Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. Wang Y; Wang X; Zhao H; Liang B; Du Q J Chemother; 2012 Dec; 24(6):348-57. PubMed ID: 23174100 [TBL] [Abstract][Full Text] [Related]
19. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Sui M; Chen F; Chen Z; Fan W Int J Cancer; 2006 Aug; 119(3):712-7. PubMed ID: 16496381 [TBL] [Abstract][Full Text] [Related]
20. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Miyake H; Chi KN; Gleave ME Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]